Summary
27F0 Chart
Wall Street Analysts Believe KALA BIO (KALA) Could Rally 74.73%: Here's is How to Trade
The mean of analysts' price targets for KALA BIO (KALA) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
KALA BIO (KALA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
KALA BIO (KALA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
KALA BIO (KALA) Moves to Strong Buy: Rationale Behind the Upgrade
KALA BIO (KALA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Kala Pharmaceuticals, Inc. (27F0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Kala Pharmaceuticals, Inc. ever had a stock split?
Kala Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | R. Kim Brazzell CEO | XMUN Exchange | US4831192020 ISIN |
| US Country | 38 Employees | - Last Dividend | 21 Oct 2022 Last Split | 20 Jul 2017 IPO Date |
Overview
KALA BIO, Inc., originally known as Kala Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical entity dedicated to pioneering treatments for eye-related conditions. With its foundation laid in 2009 and based in Arlington, Massachusetts, the company has transitioned its name to KALA BIO, Inc. in August 2023. It marks its presence in the pharmaceutical industry by steering the discovery, development, and eventual commercialization of innovative therapies designed to tackle a variety of eye diseases, leveraging cutting-edge technology and scientific advances to fulfil unmet medical needs.
Products and Services
- KPI-012: Currently undergoing a Phase 2b clinical trial, KPI-012 is a promising therapeutic candidate aimed at treating persistent corneal epithelial defects (PCED). This condition represents a challenging ocular surface disorder, and KPI-012's development reflects KALA BIO's commitment to addressing hard-to-treat eye diseases.
- EYSUVIS: Specifically formulated for the short-term alleviation of dry eye disease symptoms, EYSUVIS stands out as a key product. It aims at mitigating the signs and discomfort associated with dry eye syndrome, offering patients a much-needed respite from this widespread and often debilitating condition.
- INVELTYS: As an ocular steroid designed for topical administration twice a day, INVELTYS is approved for the management of post-operative inflammation and pain following ocular surgery. Its development underscores the company's focus on improving post-surgical outcomes and enhancing patient recovery experiences.
- KPI-014: Still in the preclinical development phase, KPI-014 targets the treatment of rare inherited retinal diseases. By venturing into this challenging domain, KALA BIO underscores its commitment to expanding the horizons of ophthalmic medicine and bringing hope to patients with limited treatment options.
Contact Information
